NRX:CC - NurExone Biologic Inc. Retains Services of Thesis Capital Inc
Bnei-Brak, Israel--(Newsfile Corp. - July 6, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) ("NurExone" or the "Company") is pleased to announce that it has retained the services of Thesis Capital Inc. ("Thesis") of Toronto, Ontario, a leading capital markets advisory firm servicing Canadian small cap companies across the North American markets. Thesis will provide investor relations and advisory services to the Company, subject to TSX Venture Exchange ("TSXV") approval.
Pursuant to a consulting agreement dated July 5, 2022, Thesis will be paid up to $78,000 plus reasonable out of pocket expenses for its services. The engagement is for an initial term of twelve months and month to month thereafter, unless terminated by either party providing written notice at least 30 days prior to the end of the term.
About NurExone Biologic Inc.
NurExone is a pharmaceutical company developing a biological extracellular vesicles (EV)-based technology drug platform. This is a unique advanced treatment for reversing paralysis and improving the quality of life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified siRNA sequence. This technology, which has been successfully used in animal studies, after it is approved in clinical trials, can be used to treat various conditions such as spinal cord injury, traumatic brain injury, and other brain and neurological indications.
NurExone holds an exclusive worldwide license to develop and commercialize the technology by the Technion - Israel Institute of Technology, Haifa and Tel Aviv University, both located in Israel. As well, the Company has recently obtained an additional exclusive global license to an exosome manufacturing process developed at the Technion - Israel Institute of Technology, Haifa. NurExone will be responsible for ongoing exosome research, management of clinical studies and commercialization of the technology for different indications not limited to the central nervous system.
About Thesis Capital Inc.
Thesis is a leading independent capital markets advisory firm catering to non-resource Canadian issuers. Thesis aims to provide objective advice to public and private companies on their investor relations, communications strategy, and overall market intelligence. Thesis develops quality relationships with key stakeholders involved in the entire capital markets industry.
ON BEHALF OF THE BOARD OF DIRECTORS:
Dr. Lior Shaltiel, Chief Executive Officer and Director.
Email: info@nurexone.com Phone: +972-52-4803034
READER ADVISORY
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
The securities set forth herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
FORWARD-LOOKING STATEMENTS
This press release contains certain forward-looking statements, including statements about the Company's future plans and intentions and completion of the Transaction. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/130124